Active Biotech's rights issue substantially oversubscribed
As a consequence of the rights issue, the number of shares and votes in the company increases with 12,810,447 to 64,052,238 and the share capital with approximately SEK 48,286,964.30 to SEK 241,434,832.81.
The rights issue will provide Active Biotech with approximately SEK 256 M before issue expenses.
Last day for trading in interim shares (BTA) is June 30, 2009. Trading in the new shares on NASDAQ OMX Stockholm is expected to commence on or about June 30, 2009, or already prior to that depending on when the Swedish Companies Registration Office has registered the new issue.
Lund 15 June 2009
Active Biotech AB (publ)
President & CEO
For further information, please contact:
Tomas Leanderson, President & CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0) 46 19 20 44
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please visit www.activebiotech.com
for more information.
Active Biotech AB
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 08:30 am CET on June 15, 2009.
This press release does not constitute an offer of any securities of Active Biotech. The rights issue is not directed to shareholders or other investors domiciled in the United States, Canada, Japan or Australia, or in any other country where participation in the issue would require additional prospectuses, registration or measures other than those pursuant to Swedish law or would conflict with regulations in such country. No shares, interim shares, subscription rights or other securities issued by Active Biotech have been or will be registered in accordance with the United States Securities Act of 1933, or in accordance with any securities legislation in any state of the United States or any province in Canada. Accordingly, no new shares, interim shares, subscription rights or other securities issued by Active Biotech may be transferred or offered for sale in the United States or Canada, other than in such exceptional cases that do not require registration.